IN VITRO EFFECTS OF MEVASTATIN AND BIOLOGICAL PREPARATIONS UPON ACTIVATION OF EBV-SPECIFIC CD4+T LYMPHOCYTES FROM THE PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract

Abstract. Present study concerned in vitro modifying effects of mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra upon antigen-induced activation of peripheral EBV-specific CD4+T-lymphocytes from the patients with rheumatoid arthritis (RA). When compared with healthy persons, the RA patients have shown significantly decreased concentrations of antigen-activated EBV-specific CD4+T-cells. In healthy donors, mevastatin, infliximab, r-met-Hu-sTNF-RI and IL-1ra did not influence the CD4+, IFNγ+ cell concentrations. Neither there were any effects of the abovementioned drugs upon the numbers of EBV-specific CD4+T-cell subset among cultured mononuclear cells from RA patients. Thus, the cells from RA patients exhibit a decreased in vitro antigen-induced activation of EBV-specific CD4+T-cells, whereas statins and biological agents do not promote suppression of EBV-specific activation of CD4+T-cells. (Med. Immunol., 2011, vol. 13, n 2-3, pp 285-290)

Keywords

• rheumathoid arthritis
• epstein–barr virus
• treatment
• statins
• biological drugs